Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer to assume Aleve marketing by year-end under Roche joint venture.

This article was originally published in The Tan Sheet

Executive Summary

BAYER TO ASSUME ALEVE MARKETING BY END OF 1996 under a 50/50 joint venture agreement with Roche announced by the companies on Sept. 16. Bayer's Morris Township, N.J.-based Consumer Care Division will handle U.S. sales and marketing of the joint venture brands, which also include Roche's Femstat 3 vaginal yeast infection treatment and four Bayer brands: Actron and Vanquish analgesics; Midol menstrual discomfort products; and Mycelex-7 yeast infection treatment.

You may also be interested in...



Prilosec OTC Has Retailers Staying Up Late; “BurnTown” Preview Underway

Wal-Mart is shipping "pre-awareness" promotional kits for Procter & Gamble's Prilosec OTC (omeprazole) to its stores in anticipation of the heartburn prevention drug's Sept. 15 launch

Prilosec OTC Has Retailers Staying Up Late; “BurnTown” Preview Underway

Wal-Mart is shipping "pre-awareness" promotional kits for Procter & Gamble's Prilosec OTC (omeprazole) to its stores in anticipation of the heartburn prevention drug's Sept. 15 launch

Prilosec OTC Has Retailers Staying Up Late; “BurnTown” Preview Underway

Wal-Mart is shipping "pre-awareness" promotional kits for Procter & Gamble's Prilosec OTC (omeprazole) to its stores in anticipation of the heartburn prevention drug's Sept. 15 launch

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel